Cellectis Stock Falls 4.65% at Midday After a 20% Surge Over the Week

Recent Surge and Technical Indicators

The stock had jumped 12% on Monday, November 24, continuing a notable upward trend with a gain of 35.1% over a week. This surge followed the publication on November 19 of a scientific article in Nature Communications demonstrating that single-stranded circular DNA (CssDNA) constitutes an effective non-viral DNA matrix for gene insertion in hematopoietic stem cells. The CssDNA method shows a gene insertion efficiency 3 to 5 times higher than that of single-stranded linear DNA, with insertion rates exceeding 40%. Over three months, Cellectis' stock has gained 80.33%, massively outperforming the CAC 40, which has only seen an increase of 11.13% over a year. The volumes traded at mid-session represent 0.61% of the capital, in a market context slowed down by the upcoming Thanksgiving holiday in the United States. The observed decline this Wednesday occurs in a technical environment revealing an overheating of the stock. The RSI (Relative Strength Index) reaches 81, a level significantly above the overbought threshold set at 70, indicating excessive buying pressure that generally requires a pause or correction. The price also moves very close to the upper Bollinger band located at 4.53 euros, a zone that often marks a point of technical resistance. This technical consolidation thus appears as a logical breather after the sharp acceleration of recent days, especially since the Stochastic signal now shows a selling position.

Financial Health and Scientific Breakthroughs

Beyond the scientific breakthrough announced in mid-November, Cellectis had cash and cash equivalents of 225 million dollars as of September 30, 2025, compared to 264 million dollars on December 31, 2024. The biotechnology company estimates it can fund its activities until the second half of 2027 with these resources. The company presented encouraging results at the beginning of November for its lasme-cel candidate with an overall response rate of 68% in Phase 1, reaching 83% at the dose recommended for Phase 2 and 100% in the target population of Phase 2. Cellectis also announced that it would present new clinical data on its eti-cel program at the annual congress of the American Society of Hematology (ASH) to be held from December 6 to 9 in Orlando. The MACD (Moving Average Convergence Divergence) indicator confirms the underlying bullish dynamic despite the day's correction. The MACD line at 0.25 remains well above the signal line at 0.08, with a positive histogram of 0.17, indicating a bullish trend that remains intact in the medium term. The 50-day moving average is set at 3.28 euros, well below the current price, confirming that the recent upward movement is part of an ascending fundamental trend. The stock has progressed steadily over several months, as evidenced by the growing gap between the 50 and 200-day moving averages.

Market Volatility and Future Outlook

The high volatility of the stock, measured at 25.51% over a month, reflects the speculative nature of the value and the intensity of recent movements. The resistance threshold identified at 4.55 euros now constitutes a near target for buyers, while the support is located at 2.86 euros, offering a substantial safety margin. Citizens reiterated its Market Outperformance rating and its price target of 8 dollars on Cellectis, while the stock is currently trading at 4.14 dollars on the Nasdaq. Investors will closely monitor the presentations scheduled for early December at the ASH congress, which could provide new catalysts for the stock. In the immediate term, the technical consolidation observed at mid-session appears healthy after the recent strong progression. The low volumes, linked to the American context of Thanksgiving, however, limit the scope of this movement. The next sessions will be decisive in assessing whether the stock can durably surpass the psychological threshold of 4.55 euros or if it requires a more marked correction to digest its recent gains before continuing its ascent.